Form 4: TriSalus Life Sciences Executive Marshak Reports Stock Transactions
SEC Filing
Richard Marshak, Chief Commercial Officer of TriSalus Life Sciences, reports acquisition and disposal of common stock related to vested RSUs.
Summary
- Richard Marshak, the Chief Commercial Officer of TriSalus Life Sciences, filed a Form 4 detailing changes in beneficial ownership.
- On May 19, 2025, Marshak acquired 21,428 shares of common stock at a price of $5.18 per share.
- On the same day, Marshak disposed of 6,597 shares of common stock at $5.18 per share to cover tax liabilities associated with the vested RSUs.
- Following these transactions, Marshak beneficially owns 69,101 shares of TriSalus Life Sciences common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in insider ownership.
Key Dates
| Date | Description |
|---|---|
| 05/19/2025 | Date of stock acquisition and disposal. |
| 05/21/2025 | Date of signature by Attorney-in-Fact. |
Keywords
Form 4, TriSalus Life Sciences, Marshak, Beneficial Ownership, Stock Transaction, TLSI, RSU
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.